CSL Ltd. plunged the most on record after the Australian biotechnology company cut its full-year outlook and flagged about $5 ...

CSL now expects weaker full-year revenue and profit as plasma, China pricing, and Vifor pressures weigh on performance.

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Is there more pain in store for CSL shareholders? The post Where to from here for CSL shares according to Macquarie appeared ...

Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter CSL Limited has announced the ...

CSL (AU:CSL) has released an update. CSL Limited has announced the issuance of 1,454 unquoted equity securities, indicating a strategic move to bolster its financial structure. This development could ...

CSL’s share price has been hammered over the past year. Is the sell-off now starting to look overdone? Let's take a closer ...

Ladies and gentlemen, good morning and welcome to CSL's Full-Year Results Call for Fiscal 2023. It's Mark Dehring speaking, and joining me online is Paul McKenzie, CSL's Chief Executive Officer; Joy ...

Approaching the final week of November CSL Ltd ADR (OTCMKTS: CSLLY) received some good news as the United States Food and Drug Administration approved CSL Behring’s new gene therapy drug, HEMEGENIX ...

CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, has released its first Corporate Responsibility Report, combining information about the Company’s economic, social and ...

Ladies and gentlemen, good morning, and welcome to CSL's first half results call for fiscal 2024. It's Mark Dehring speaking, and I'm pleased to be joined by several of CSL's leadership team. With me ...

CSL Ltd shares are being hammered after the Australian biotech released another painful update to the market, with the stock ...